Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Peptide Based Gastrointestinal Disorders Therapeutics market report explains the definition, types, applications, major countries, and major players of the Peptide Based Gastrointestinal Disorders Therapeutics market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.
The report contains qualitative and quantitative analysis of the entire industry.
The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.
By Player:
Ironwood Pharmaceuticals
Takeda Pharmaceutical
Astellas Pharma
Allergan
Shire
By Type:
Teduglutide
Linaclotide
Others
By End-User:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region:
North America
-
United States
-
Canada
-
Mexico
Europe
-
Germany
-
UK
-
Spain
-
France
-
Italy
-
Denmark
-
Finland
-
Norway
-
Sweden
-
Poland
-
Russia
-
Turkey
Asia-Pacific
-
China
-
Japan
-
India
-
South Korea
-
Pakistan
-
Bangladesh
-
Indonesia
-
Thailand
-
Singapore
-
Malaysia
-
Philippines
-
Vietnam
-
Others
South America
-
Brazil
-
Colombia
-
Chile
-
Argentina
-
Venezuela
-
Peru
-
Puerto Rico
-
Ecuador
-
Others
GCC
-
Bahrain
-
Kuwait
-
Oman
-
Qatar
-
Saudi Arabia
-
United Arab Emirates
Africa
-
Nigeria
-
South Africa
-
Egypt
-
Algeriat
-
Others
Oceania
-
Australia
-
New Zealand
TABLE OF CONTENT
1. Global Peptide Based Gastrointestinal Disorders Therapeutics Executive Summary
-
1.1 Introduction
-
1.2 Market Panorama, 2022
2 Coronavirus Impact
-
2.1 Peptide Based Gastrointestinal Disorders Therapeutics Outlook to 2028- Original Forecasts
-
2.2 Peptide Based Gastrointestinal Disorders Therapeutics Outlook to 2028- COVID-19 Affected Forecasts
-
2.3 Impact on Industry
3 Strategic Analytics to Boost Productivity and Profitability
-
3.1 Potential Market Drivers and Opportunities
-
3.2 New Challenges and Strategies
-
3.3 Short Term and Long Term Peptide Based Gastrointestinal Disorders Therapeutics Market Trends
4 Key Inferences
5 Market Overview
-
5.1 Current Market Scenario
-
5.2 Porter's Five Forces Analysis
-
5.2.1 Bargaining Power of Suppliers
-
5.2.2 Bargaining Power of Consumers
-
5.2.3 Threat of New Entrants
-
5.2.4 Threat of Substitute Product and Services
-
5.2.5 Competitive Rivalry within the Industry
6 Global Peptide Based Gastrointestinal Disorders Therapeutics Market- Recent Developments
-
6.1 Peptide Based Gastrointestinal Disorders Therapeutics Market News and Developments
-
6.2 Peptide Based Gastrointestinal Disorders Therapeutics Market Deals Landscape
7 Peptide Based Gastrointestinal Disorders Therapeutics Raw Materials and Cost Structure Analysis
-
7.1 Peptide Based Gastrointestinal Disorders Therapeutics Key Raw Materials
-
7.2 Peptide Based Gastrointestinal Disorders Therapeutics Price Trend of Key Raw Materials
-
7.3 Peptide Based Gastrointestinal Disorders Therapeutics Key Suppliers of Raw Materials
-
7.4 Peptide Based Gastrointestinal Disorders Therapeutics Market Concentration Rate of Raw Materials
-
7.5 Peptide Based Gastrointestinal Disorders Therapeutics Cost Structure Analysis
-
7.5.1 Peptide Based Gastrointestinal Disorders Therapeutics Raw Materials Analysis
-
7.5.2 Peptide Based Gastrointestinal Disorders Therapeutics Labor Cost Analysis
-
7.5.3 Peptide Based Gastrointestinal Disorders Therapeutics Manufacturing Expenses Analysis
8 Global Peptide Based Gastrointestinal Disorders Therapeutics Import and Export Analysis (Top 10 Countries)
-
8.1 Global Peptide Based Gastrointestinal Disorders Therapeutics Import by Region (Top 10 Countries) (2017-2028)
-
8.2 Global Peptide Based Gastrointestinal Disorders Therapeutics Export by Region (Top 10 Countries) (2017-2028)
9 Global Peptide Based Gastrointestinal Disorders Therapeutics Market Outlook by Types and Applications to 2022
-
9.1 Global Peptide Based Gastrointestinal Disorders Therapeutics Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Teduglutide Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Linaclotide Consumption and Growth Rate (2017-2022)
-
9.1.3 Global Others Consumption and Growth Rate (2017-2022)
-
9.2 Global Peptide Based Gastrointestinal Disorders Therapeutics Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Hospital Pharmacies Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Retail Pharmacies Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Online Pharmacies Consumption and Growth Rate (2017-2022)
10 Region and Country-wise Peptide Based Gastrointestinal Disorders Therapeutics Market Analysis and Outlook till 2022
-
10.1 Global Peptide Based Gastrointestinal Disorders Therapeutics Consumption (2017-2022)
-
10.2 North America Consumption Analysis
-
10.2.1 United States Peptide Based Gastrointestinal Disorders Therapeutics Consumption (2017-2022)
-
10.2.2 Canada Peptide Based Gastrointestinal Disorders Therapeutics Consumption (2017-2022)
-
10.2.3 Mexico Peptide Based Gastrointestinal Disorders Therapeutics Consumption (2017-2022)
-
10.3 Europe Consumption Analysis
-
10.3.1 Germany Peptide Based Gastrointestinal Disorders Therapeutics Consumption (2017-2022)
-
10.3.2 UK Peptide Based Gastrointestinal Disorders Therapeutics Consumption (2017-2022)
-
10.3.3 Spain Peptide Based Gastrointestinal Disorders Therapeutics Consumption (2017-2022)
-
10.3.4 Belgium Peptide Based Gastrointestinal Disorders Therapeutics Consumption (2017-2022)
-
10.3.5 France Peptide Based Gastrointestinal Disorders Therapeutics Consumption (2017-2022)
-
10.3.6 Italy Peptide Based Gastrointestinal Disorders Therapeutics Consumption (2017-2022)
-
10.3.7 Denmark Peptide Based Gastrointestinal Disorders Therapeutics Consumption (2017-2022)
-
10.3.8 Finland Peptide Based Gastrointestinal Disorders Therapeutics Consumption (2017-2022)
-
10.3.9 Norway Peptide Based Gastrointestinal Disorders Therapeutics Consumption (2017-2022)
-
10.3.10 Sweden Peptide Based Gastrointestinal Disorders Therapeutics Consumption (2017-2022)
-
10.3.11 Poland Peptide Based Gastrointestinal Disorders Therapeutics Consumption (2017-2022)
-
10.3.12 Russia Peptide Based Gastrointestinal Disorders Therapeutics Consumption (2017-2022)
-
10.3.13 Turkey Peptide Based Gastrointestinal Disorders Therapeutics Consumption (2017-2022)
-
10.4 APAC Consumption Analysis
-
10.4.1 China Peptide Based Gastrointestinal Disorders Therapeutics Consumption (2017-2022)
-
10.4.2 Japan Peptide Based Gastrointestinal Disorders Therapeutics Consumption (2017-2022)
-
10.4.3 India Peptide Based Gastrointestinal Disorders Therapeutics Consumption (2017-2022)
-
10.4.4 South Korea Peptide Based Gastrointestinal Disorders Therapeutics Consumption (2017-2022)
-
10.4.5 Pakistan Peptide Based Gastrointestinal Disorders Therapeutics Consumption (2017-2022)
-
10.4.6 Bangladesh Peptide Based Gastrointestinal Disorders Therapeutics Consumption (2017-2022)
-
10.4.7 Indonesia Peptide Based Gastrointestinal Disorders Therapeutics Consumption (2017-2022)
-
10.4.8 Thailand Peptide Based Gastrointestinal Disorders Therapeutics Consumption (2017-2022)
-
10.4.9 Singapore Peptide Based Gastrointestinal Disorders Therapeutics Consumption (2017-2022)
-
10.4.10 Malaysia Peptide Based Gastrointestinal Disorders Therapeutics Consumption (2017-2022)
-
10.4.11 Philippines Peptide Based Gastrointestinal Disorders Therapeutics Consumption (2017-2022)
-
10.4.12 Vietnam Peptide Based Gastrointestinal Disorders Therapeutics Consumption (2017-2022)
-
10.5 South America Consumption Analysis
-
10.5.1 Brazil Peptide Based Gastrointestinal Disorders Therapeutics Consumption (2017-2022)
-
10.5.2 Colombia Peptide Based Gastrointestinal Disorders Therapeutics Consumption (2017-2022)
-
10.5.3 Chile Peptide Based Gastrointestinal Disorders Therapeutics Consumption (2017-2022)
-
10.5.4 Argentina Peptide Based Gastrointestinal Disorders Therapeutics Consumption (2017-2022)
-
10.5.5 Venezuela Peptide Based Gastrointestinal Disorders Therapeutics Consumption (2017-2022)
-
10.5.6 Peru Peptide Based Gastrointestinal Disorders Therapeutics Consumption (2017-2022)
-
10.5.7 Puerto Rico Peptide Based Gastrointestinal Disorders Therapeutics Consumption (2017-2022)
-
10.5.8 Ecuador Peptide Based Gastrointestinal Disorders Therapeutics Consumption (2017-2022)
-
10.6 GCC Consumption Analysis
-
10.6.1 Bahrain Peptide Based Gastrointestinal Disorders Therapeutics Consumption (2017-2022)
-
10.6.2 Kuwait Peptide Based Gastrointestinal Disorders Therapeutics Consumption (2017-2022)
-
10.6.3 Oman Peptide Based Gastrointestinal Disorders Therapeutics Consumption (2017-2022)
-
10.6.4 Qatar Peptide Based Gastrointestinal Disorders Therapeutics Consumption (2017-2022)
-
10.6.5 Saudi Arabia Peptide Based Gastrointestinal Disorders Therapeutics Consumption (2017-2022)
-
10.6.6 United Arab Emirates Peptide Based Gastrointestinal Disorders Therapeutics Consumption (2017-2022)
-
10.7 Africa Consumption Analysis
-
10.7.1 Nigeria Peptide Based Gastrointestinal Disorders Therapeutics Consumption (2017-2022)
-
10.7.2 South Africa Peptide Based Gastrointestinal Disorders Therapeutics Consumption (2017-2022)
-
10.7.3 Egypt Peptide Based Gastrointestinal Disorders Therapeutics Consumption (2017-2022)
-
10.7.4 Algeria Peptide Based Gastrointestinal Disorders Therapeutics Consumption (2017-2022)
-
10.8 Oceania Consumption Analysis
-
10.8.1 Australia Peptide Based Gastrointestinal Disorders Therapeutics Consumption (2017-2022)
-
10.8.2 New Zealand Peptide Based Gastrointestinal Disorders Therapeutics Consumption (2017-2022)
11 Global Peptide Based Gastrointestinal Disorders Therapeutics Competitive Analysis
-
11.1 Ironwood Pharmaceuticals
-
11.1.1 Ironwood Pharmaceuticals Company Details
-
11.1.2 Ironwood Pharmaceuticals Peptide Based Gastrointestinal Disorders Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
11.1.3 Ironwood Pharmaceuticals Peptide Based Gastrointestinal Disorders Therapeutics Main Business and Markets Served
-
11.1.4 Ironwood Pharmaceuticals Peptide Based Gastrointestinal Disorders Therapeutics Product Portfolio
-
11.1.5 Recent Research and Development Strategies
-
11.2 Takeda Pharmaceutical
-
11.2.1 Takeda Pharmaceutical Company Details
-
11.2.2 Takeda Pharmaceutical Peptide Based Gastrointestinal Disorders Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
11.2.3 Takeda Pharmaceutical Peptide Based Gastrointestinal Disorders Therapeutics Main Business and Markets Served
-
11.2.4 Takeda Pharmaceutical Peptide Based Gastrointestinal Disorders Therapeutics Product Portfolio
-
11.2.5 Recent Research and Development Strategies
-
11.3 Astellas Pharma
-
11.3.1 Astellas Pharma Company Details
-
11.3.2 Astellas Pharma Peptide Based Gastrointestinal Disorders Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
11.3.3 Astellas Pharma Peptide Based Gastrointestinal Disorders Therapeutics Main Business and Markets Served
-
11.3.4 Astellas Pharma Peptide Based Gastrointestinal Disorders Therapeutics Product Portfolio
-
11.3.5 Recent Research and Development Strategies
-
11.4 Allergan
-
11.4.1 Allergan Company Details
-
11.4.2 Allergan Peptide Based Gastrointestinal Disorders Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
11.4.3 Allergan Peptide Based Gastrointestinal Disorders Therapeutics Main Business and Markets Served
-
11.4.4 Allergan Peptide Based Gastrointestinal Disorders Therapeutics Product Portfolio
-
11.4.5 Recent Research and Development Strategies
-
11.5 Shire
-
11.5.1 Shire Company Details
-
11.5.2 Shire Peptide Based Gastrointestinal Disorders Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
11.5.3 Shire Peptide Based Gastrointestinal Disorders Therapeutics Main Business and Markets Served
-
11.5.4 Shire Peptide Based Gastrointestinal Disorders Therapeutics Product Portfolio
-
11.5.5 Recent Research and Development Strategies
12 Global Peptide Based Gastrointestinal Disorders Therapeutics Market Outlook by Types and Applications to 2028
-
12.1 Global Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast and Growth Rate by Type (2022-2028)
-
12.1.1 Global Teduglutide Consumption Forecast and Growth Rate (2022-2028)
-
12.1.2 Global Linaclotide Consumption Forecast and Growth Rate (2022-2028)
-
12.1.3 Global Others Consumption Forecast and Growth Rate (2022-2028)
-
12.2 Global Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast and Growth Rate by Application (2022-2028)
-
12.2.1 Global Hospital Pharmacies Consumption Forecast and Growth Rate (2022-2028)
-
12.2.2 Global Retail Pharmacies Consumption Forecast and Growth Rate (2022-2028)
-
12.2.3 Global Online Pharmacies Consumption Forecast and Growth Rate (2022-2028)
13 Country-wise Peptide Based Gastrointestinal Disorders Therapeutics Market Analysis and Outlook to 2028
-
13.1 Global Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast (2022-2028)
-
13.2 North America Consumption Analysis
-
13.2.1 United States Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast (2022-2028)
-
13.2.2 Canada Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast (2022-2028)
-
13.2.3 Mexico Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast (2022-2028)
-
13.3 Europe Consumption Analysis
-
13.3.1 Germany Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast (2022-2028)
-
13.3.2 UK Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast (2022-2028)
-
13.3.3 Spain Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast (2022-2028)
-
13.3.4 Belgium Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast (2022-2028)
-
13.3.5 France Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast (2022-2028)
-
13.3.6 Italy Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast (2022-2028)
-
13.3.7 Denmark Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast (2022-2028)
-
13.3.8 Finland Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast (2022-2028)
-
13.3.9 Norway Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast (2022-2028)
-
13.3.10 Sweden Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast (2022-2028)
-
13.3.11 Poland Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast (2022-2028)
-
13.3.12 Russia Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast (2022-2028)
-
13.3.13 Turkey Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast (2022-2028)
-
13.4 APAC Consumption Analysis
-
13.4.1 China Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast (2022-2028)
-
13.4.2 Japan Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast (2022-2028)
-
13.4.3 India Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast (2022-2028)
-
13.4.4 South Korea Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast (2022-2028)
-
13.4.5 Pakistan Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast (2022-2028)
-
13.4.6 Bangladesh Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast (2022-2028)
-
13.4.7 Indonesia Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast (2022-2028)
-
13.4.8 Thailand Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast (2022-2028)
-
13.4.9 Singapore Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast (2022-2028)
-
13.4.10 Malaysia Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast (2022-2028)
-
13.4.11 Philippines Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast (2022-2028)
-
13.4.12 Vietnam Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast (2022-2028)
-
13.5 South America Consumption Analysis
-
13.5.1 Brazil Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast (2022-2028)
-
13.5.2 Colombia Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast (2022-2028)
-
13.5.3 Chile Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast (2022-2028)
-
13.5.4 Argentina Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast (2022-2028)
-
13.5.5 Venezuela Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast (2022-2028)
-
13.5.6 Peru Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast (2022-2028)
-
13.5.7 Puerto Rico Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast (2022-2028)
-
13.5.8 Ecuador Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast (2022-2028)
-
13.6 GCC Consumption Analysis
-
13.6.1 Bahrain Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast (2022-2028)
-
13.6.2 Kuwait Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast (2022-2028)
-
13.6.3 Oman Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast (2022-2028)
-
13.6.4 Qatar Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast (2022-2028)
-
13.6.5 Saudi Arabia Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast (2022-2028)
-
13.6.6 United Arab Emirates Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast (2022-2028)
-
13.7 Africa Consumption Analysis
-
13.7.1 Nigeria Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast (2022-2028)
-
13.7.2 South Africa Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast (2022-2028)
-
13.7.3 Egypt Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast (2022-2028)
-
13.7.4 Algeria Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast (2022-2028)
-
13.8 Oceania Consumption Analysis
-
13.8.1 Australia Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast (2022-2028)
-
13.8.2 New Zealand Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast (2022-2028)
14 Conclusions
The List of Tables and Figures
-
Table Definition of Peptide Based Gastrointestinal Disorders Therapeutics
-
Figure of Peptide Based Gastrointestinal Disorders Therapeutics Picture
-
Table Global Peptide Based Gastrointestinal Disorders Therapeutics Import by Region (Top 10 Countries) (2017-2028)
-
Table Global Peptide Based Gastrointestinal Disorders Therapeutics Export by Region (Top 10 Countries) (2017-2028)
-
Figure Global Teduglutide Consumption and Growth Rate (2017-2022)
-
Figure Global Linaclotide Consumption and Growth Rate (2017-2022)
-
Figure Global Others Consumption and Growth Rate (2017-2022)
-
Figure Global Hospital Pharmacies Consumption and Growth Rate (2017-2022)
-
Figure Global Retail Pharmacies Consumption and Growth Rate (2017-2022)
-
Figure Global Online Pharmacies Consumption and Growth Rate (2017-2022)
-
Figure Global Peptide Based Gastrointestinal Disorders Therapeutics Consumption by Country (2017-2022)
-
Table North America Peptide Based Gastrointestinal Disorders Therapeutics Consumption by Country (2017-2022)
-
Figure United States Peptide Based Gastrointestinal Disorders Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Canada Peptide Based Gastrointestinal Disorders Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Mexico Peptide Based Gastrointestinal Disorders Therapeutics Consumption and Growth Rate (2017-2022)
-
Table Europe Peptide Based Gastrointestinal Disorders Therapeutics Consumption by Country (2017-2022)
-
Figure Germany Peptide Based Gastrointestinal Disorders Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure UK Peptide Based Gastrointestinal Disorders Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Spain Peptide Based Gastrointestinal Disorders Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Belgium Peptide Based Gastrointestinal Disorders Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure France Peptide Based Gastrointestinal Disorders Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Italy Peptide Based Gastrointestinal Disorders Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Denmark Peptide Based Gastrointestinal Disorders Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Finland Peptide Based Gastrointestinal Disorders Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Norway Peptide Based Gastrointestinal Disorders Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Sweden Peptide Based Gastrointestinal Disorders Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Poland Peptide Based Gastrointestinal Disorders Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Russia Peptide Based Gastrointestinal Disorders Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Turkey Peptide Based Gastrointestinal Disorders Therapeutics Consumption and Growth Rate (2017-2022)
-
Table APAC Peptide Based Gastrointestinal Disorders Therapeutics Consumption by Country (2017-2022)
-
Figure China Peptide Based Gastrointestinal Disorders Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Japan Peptide Based Gastrointestinal Disorders Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure India Peptide Based Gastrointestinal Disorders Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure South Korea Peptide Based Gastrointestinal Disorders Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Pakistan Peptide Based Gastrointestinal Disorders Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Bangladesh Peptide Based Gastrointestinal Disorders Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Indonesia Peptide Based Gastrointestinal Disorders Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Thailand Peptide Based Gastrointestinal Disorders Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Singapore Peptide Based Gastrointestinal Disorders Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Malaysia Peptide Based Gastrointestinal Disorders Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Philippines Peptide Based Gastrointestinal Disorders Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Vietnam Peptide Based Gastrointestinal Disorders Therapeutics Consumption and Growth Rate (2017-2022)
-
Table South America Peptide Based Gastrointestinal Disorders Therapeutics Consumption by Country (2017-2022)
-
Figure Brazil Peptide Based Gastrointestinal Disorders Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Colombia Peptide Based Gastrointestinal Disorders Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Chile Peptide Based Gastrointestinal Disorders Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Argentina Peptide Based Gastrointestinal Disorders Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Venezuela Peptide Based Gastrointestinal Disorders Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Peru Peptide Based Gastrointestinal Disorders Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Puerto Rico Peptide Based Gastrointestinal Disorders Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Ecuador Peptide Based Gastrointestinal Disorders Therapeutics Consumption and Growth Rate (2017-2022)
-
Table GCC Peptide Based Gastrointestinal Disorders Therapeutics Consumption by Country (2017-2022)
-
Figure Bahrain Peptide Based Gastrointestinal Disorders Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Kuwait Peptide Based Gastrointestinal Disorders Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Oman Peptide Based Gastrointestinal Disorders Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Qatar Peptide Based Gastrointestinal Disorders Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Saudi Arabia Peptide Based Gastrointestinal Disorders Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure United Arab Emirates Peptide Based Gastrointestinal Disorders Therapeutics Consumption and Growth Rate (2017-2022)
-
Table Africa Peptide Based Gastrointestinal Disorders Therapeutics Consumption by Country (2017-2022)
-
Figure Nigeria Peptide Based Gastrointestinal Disorders Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure South Africa Peptide Based Gastrointestinal Disorders Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Egypt Peptide Based Gastrointestinal Disorders Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Algeria Peptide Based Gastrointestinal Disorders Therapeutics Consumption and Growth Rate (2017-2022)
-
Table Oceania Peptide Based Gastrointestinal Disorders Therapeutics Consumption by Country (2017-2022)
-
Figure Australia Peptide Based Gastrointestinal Disorders Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure New Zealand Peptide Based Gastrointestinal Disorders Therapeutics Consumption and Growth Rate (2017-2022)
-
Table Ironwood Pharmaceuticals Company Details
-
Table Ironwood Pharmaceuticals Peptide Based Gastrointestinal Disorders Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table Ironwood Pharmaceuticals Peptide Based Gastrointestinal Disorders Therapeutics Main Business and Markets Served
-
Table Ironwood Pharmaceuticals Peptide Based Gastrointestinal Disorders Therapeutics Product Portfolio
-
Table Takeda Pharmaceutical Company Details
-
Table Takeda Pharmaceutical Peptide Based Gastrointestinal Disorders Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table Takeda Pharmaceutical Peptide Based Gastrointestinal Disorders Therapeutics Main Business and Markets Served
-
Table Takeda Pharmaceutical Peptide Based Gastrointestinal Disorders Therapeutics Product Portfolio
-
Table Astellas Pharma Company Details
-
Table Astellas Pharma Peptide Based Gastrointestinal Disorders Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table Astellas Pharma Peptide Based Gastrointestinal Disorders Therapeutics Main Business and Markets Served
-
Table Astellas Pharma Peptide Based Gastrointestinal Disorders Therapeutics Product Portfolio
-
Table Allergan Company Details
-
Table Allergan Peptide Based Gastrointestinal Disorders Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table Allergan Peptide Based Gastrointestinal Disorders Therapeutics Main Business and Markets Served
-
Table Allergan Peptide Based Gastrointestinal Disorders Therapeutics Product Portfolio
-
Table Shire Company Details
-
Table Shire Peptide Based Gastrointestinal Disorders Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table Shire Peptide Based Gastrointestinal Disorders Therapeutics Main Business and Markets Served
-
Table Shire Peptide Based Gastrointestinal Disorders Therapeutics Product Portfolio
-
Figure Global Teduglutide Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Linaclotide Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Others Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Hospital Pharmacies Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Retail Pharmacies Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Online Pharmacies Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast by Country (2022-2028)
-
Table North America Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast by Country (2022-2028)
-
Figure United States Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Canada Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Mexico Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast by Country (2022-2028)
-
Figure Germany Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure UK Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Spain Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Belgium Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure France Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Italy Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Denmark Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Finland Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Norway Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Sweden Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Poland Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Russia Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Turkey Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Table APAC Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast by Country (2022-2028)
-
Figure China Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Pakistan Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Bangladesh Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Indonesia Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Thailand Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Singapore Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Malaysia Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Philippines Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Vietnam Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Table South America Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast by Country (2022-2028)
-
Figure Brazil Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Colombia Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Chile Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Argentina Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Venezuela Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Peru Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Puerto Rico Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Ecuador Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Table GCC Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast by Country (2022-2028)
-
Figure Bahrain Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Kuwait Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Oman Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Qatar Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Saudi Arabia Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure United Arab Emirates Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Table Africa Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast by Country (2022-2028)
-
Figure Nigeria Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Africa Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Egypt Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Algeria Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Table Oceania Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast by Country (2022-2028)
-
Figure Australia Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure New Zealand Peptide Based Gastrointestinal Disorders Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
